We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FTC's Ohlhausen Sees Light At End Of Pay-For-Delay Tunnel

Law360, Washington (November 16, 2017, 2:57 PM EST) -- The Federal Trade Commission may have “finally started to turn the corner” with its crackdown on pay-for-delay patent settlements, but other efforts by branded-drug makers to stave off generic competition have increasingly caught the watchdog’s eye, acting Chairman Maureen Ohlhausen said Thursday.

Though the antitrust enforcer continues to have challenges to Hatch-Waxman Act patent settlements on its books, the FTC’s most recent review of mandatory reports of pharmaceutical patent settlements saw the number of potentially problematic deals drop after the U.S. Supreme Court’s Actavis decision paved...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.